© 1986

Neurobiology of Central D1-Dopamine Receptors

  • George R. Breese
  • Ian Creese

Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 204)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Louis C. Iorio, Allen Barnett, William Billard, Elijah H. Gold
    Pages 1-14
  3. John Hyttel, Jørn Arnt
    Pages 15-28
  4. Richard B. Mailman, David W. Schulz, Clinton D. Kilts, Mark H. Lewis, Hans Rollema, Steven Wyrick
    Pages 53-72
  5. Peter H. Andersen, Erik B. Nielsen
    Pages 73-91
  6. Ted M. Dawson, Donald R. Gehlert, James K. Wamsley
    Pages 93-118
  7. Göran Sedvall, Lars Farde, Sharon Stone-Elander, Christer Halldin
    Pages 119-124
  8. John L. Waddington, Anthony G. Molloy, Kathy M. O’Boyle, Marcellina Mashurano
    Pages 125-136
  9. T. Celeste Napier, George R. Breese
    Pages 167-188
  10. Menek Goldstein, Shigeki Kuga, Yoji Shimizu, Emanuel Meller
    Pages 189-195
  11. George R. Breese, Robert A. Mueller, T. Celeste Napier, Gary E. Duncan
    Pages 197-215
  12. Back Matter
    Pages 217-219

About this book


Our understanding of the functional mechanisms relating dopamine activity to normal and abnormal behavior has been turned "upside-down" by the recent developments described in the chapters of this volume. Heretofore, it was generally agreed that all of the pharmacological and behavioral properties ascribed to dopamine systems were mediated via activation or inhibition of the subtype of dopamine receptors termed D2. The properties of these receptors were first characterized in 1975 following their identification by receptor binding techniques utilizing 3H-butyrophenones, potent antipsychotic drugs, used in the treatment of schizophrenia. Although another subtype of dopamine receptor had already been identified a few years earlier, now termed the Dl receptor, its functional properties were unknow- other than the fact that it was associated with the activation of the enzyme adenylate cyclase. Our absence of knowledge of the behavioral functions of this receptor stemmed primarily from the lack of selective agonist and antagonists for DI receptors - drugs which did not also interact with D2 receptors. Selective agents for D2 receptors did exist and hence the behavioral roles of D2 receptors were easily ascribed. The work described in this text is primarily stimulated by the development of two selective Dl receptor drugs - the antagonist SCH 23390 and the agonist SKF 38393. The studies described herein clearly show that D1 receptors do indeed have many behavioral functions, on the surface often similar to those responses mediated by D2 receptors.


behavior biology neurobiology receptor schizophrenia

Editors and affiliations

  • George R. Breese
    • 1
  • Ian Creese
    • 2
  1. 1.University of North Carolina at Chapel HillChapel HillUSA
  2. 2.University of CaliforniaSan Diego, La JollaUSA

Bibliographic information

  • Book Title Neurobiology of Central D1-Dopamine Receptors
  • Editors George Breese
  • Series Title Advances in Experimental Medicine and Biology
  • DOI
  • Copyright Information Springer-Verlag US 1986
  • Publisher Name Springer, Boston, MA
  • eBook Packages Springer Book Archive
  • Hardcover ISBN 978-0-306-42383-3
  • Softcover ISBN 978-1-4684-5193-1
  • eBook ISBN 978-1-4684-5191-7
  • Series ISSN 0065-2598
  • Edition Number 1
  • Number of Pages VIII, 219
  • Number of Illustrations 33 b/w illustrations, 1 illustrations in colour
  • Topics Psychiatry
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals